An Israeli company has launched a clinical trial to determine if its innovative microbiome-based therapeutic could increase the responsiveness of some cancer patients to immunotherapy.
The microbiome is gut bacteria – trillions of microorganisms that live in the intestinal tract and play a role in digestion, immunity and many other aspects of health.
Rehovot-based Biomica, a subsidiary of Evogene, dosed its first patients in a Phase I clinical trial at Rambam Health Care Campus last month with a new drug – BMC128 – that is expected to help patients who do not respond to immunotherapy. Specifically, the company hopes the trial will demonstrate the safety, tolerability and preliminary clinical effectiveness of its BMC128 microbiome-based immuno-oncology drug candidate in combination with immune checkpoint inhibitor (ICI) immunotherapy.
Comments are closed.